Dr. LI is a renowned expert in gastrointestinal tumors （GI tumors） both domestically and internationally, and also a leading figure in clinical research on innovative cancer drugs in China.

He specializes in molecular targeting and immunotherapy of GI tumors, clinical research of new cancer drugs, and organize multidisciplinary diagnosis and treatment of complex solid tumors. As Leading Principal Investigator (PI), Jin LI has conducted more than 200 clinical trials including EGFR, C-MET, HER2 and other targeted drugs, as well as anti-angiogenic drugs, dual-antibodies, PD-1 inhibitors, cellular therapies and other therapies, and has helped to promote the launch of 10 anti-tumor drugs